ELQ-331 as a prototype for extremely durable chemoprotection against malaria

Martin J. Smilkstein, Sovitj Pou, Alina Krollenbrock, Lisa A. Bleyle, Rozalia A. Dodean, Lisa Frueh, David J. Hinrichs, Yuexin Li, Thomas Martinson, Myrna Y. Munar, Rolf W. Winter, Igor Bruzual, Samantha Whiteside, Aaron Nilsen, Dennis R. Koop, Jane X. Kelly, Stefan H. I. Kappe, Brandon K. Wilder, Michael K. RiscoeMalaria 2019 · DOI

Abstract: Extrapolation of these results to humans predicts that ELQ-331 should be capable of meeting and far-exceeding currently published duration-of-effect goals for anti-malarial LAI-C. Furthermore, the distinctive pharmacokinetic profile of ELQ-300 after treatment with ELQ-331 may facilitate durable protection and enable protection for far longer than 3 months. These findings suggest that ELQ-331 warrants consideration as a leading prototype for LAI-C.

Introduction

While global malaria deaths have declined, eradication remains elusive. Current vaccines are limited in efficacy and duration, prompting the Medicines for Malaria Venture (MMV) to call for Long-Acting Injectable Chemoprotection (LAI-C). The target is a single-dose intervention providing at least three months of protection. Existing drugs like atovaquone face rapid resistance, while others like primaquine carry toxicity risks. ELQ-300, a potent mitochondrial inhibitor, offers a superior resistance profile but suffers from poor oral solubility. This study evaluates ELQ-331, a prodrug of ELQ-300, as a breakthrough candidate for ultra-durable injectable protection.

The ELQ-331 Prodrug Strategy

To overcome the delivery challenges of ELQ-300, researchers synthesized several prodrug candidates. ELQ-331 emerged as the most promising lead due to its rapid conversion and favorable pharmacokinetic properties.

Chemical structures of ELQ-300 and its prodrug derivatives, including the primary candidate ELQ-331.

Methodology

The research team conducted four experimental trials using Swiss Webster and CF-1 mouse models to assess efficacy and pharmacokinetics (PK):

  • Administration: ELQ-331 was dissolved in a sesame oil vehicle and administered via a single intramuscular (IM) injection.
  • Parasite Challenge: Mice were challenged with Plasmodium yoelii (both blood-stage and sporozoites) at intervals ranging from 7 days to 5.5 months post-injection.
  • Monitoring: Efficacy was tracked using whole-body bioluminescence imaging and Giemsa-stained blood smears. Plasma concentrations were measured via LC-MS/MS and analyzed using multi-compartment PK modeling.

Key Insights and Mechanistic Findings

The "Secondary Depot" Effect

The most significant discovery was the identification of a large-capacity, slow-exchange tissue compartment. PK modeling revealed that ELQ-300 redistributes from the blood into this secondary reservoir (likely fat or specific organs), which then slowly leaks the drug back into the bloodstream. This mechanism sustains protective levels long after the initial injection site has cleared.

Rapid Conversion and Resistance Profile

ELQ-331 acts as an exceptionally efficient prodrug, converting almost immediately and completely to active ELQ-300. Furthermore, ELQ-300 maintains a superior resistance profile compared to drugs like atovaquone, with a resistance frequency of <10⁻⁸, making it safer for mass administration.

Results and Human Extrapolation

  • Ultra-Durable Protection: A single 30 mg/kg dose of ELQ-331 provided 100% protection against sporozoite challenge for 4.5 months in mice.
  • Minimum Effective Concentration (MEC): The MEC for chemoprotection was estimated to be between 60–80 nM.
  • Scaling to Humans: Using standard allometric metabolic scaling, the researchers predict that ELQ-331 can easily exceed the 3-month protection goal in humans, potentially providing protection for much longer.

Limitations and Future Directions

While promising, several hurdles remain. The current sesame oil formulation is too viscous for standard clinical needles, necessitating the development of low-viscosity vehicles or nano-suspensions. Additionally, while allometric scaling is a standard tool, clinical trials are required to confirm the "secondary depot" effect in humans. Future work will also focus on identifying the specific tissues involved in drug accumulation and finding suitable long-acting partner drugs to further mitigate resistance risks.

Summary updated

Abstract

Extrapolation of these results to humans predicts that ELQ-331 should be capable of meeting and far-exceeding currently published duration-of-effect goals for anti-malarial LAI-C. Furthermore, the distinctive pharmacokinetic profile of ELQ-300 after treatment with ELQ-331 may facilitate durable protection and enable protection for far longer than 3 months. These findings suggest that ELQ-331 warrants consideration as a leading prototype for LAI-C.
BibTeX
@inproceedings{smilkstein2019elq,
  author = {Martin J. Smilkstein and Sovitj Pou and Alina Krollenbrock and Lisa A. Bleyle and Rozalia A. Dodean and Lisa Frueh and David J. Hinrichs and Yuexin Li and Thomas Martinson and Myrna Y. Munar and Rolf W. Winter and Igor Bruzual and Samantha Whiteside and Aaron Nilsen and Dennis R. Koop and Jane X. Kelly and Stefan H. I. Kappe and Brandon K. Wilder and Michael K. Riscoe},
  title = {{ELQ-331 as a prototype for extremely durable chemoprotection against malaria}},
  booktitle = {Malaria},
  year = {2019},
  doi = {10.1186/s12936-019-2921-9},
}
Figure